Great that you came here and that you are interested in my background.
Much more important than my background is how many people I have helped so far to get rid of the side effects of targeted anticancer treatments. Read their testimonials first, before you continue reading my online CV.
Because there are so many people out there suffering from the side effects of targeted anticancer therapies.
We need to avoid the heartbreaking situation in which we are treating the cancer, and as a result, saddle the patients up with imposing, debilitating, and devastating side effects that demand more attention than the cancer and cancer treatment itself.
Can those people count on you?
2019/08 – present | Founder, Side Effects Expert, Senior Trainer, Coach & Mentor at CancerMed Side Effects Institute B.V.
I provide motivational lectures, inspiring masterclasses, and transformational intensives to an interdisciplinary and global audience. I have developed a side effects curriculum which can be found in CancerMed Valley, the online side effects campus. The entire chain of disciplines involved in the side effects of cancer medication, from biotech through healthcare professionals to the patients, take our programs.
Explore the Recommendations for my approach here.
2013/06 – 2019/08 | Founder & Adviser, Investigator, Speaker, Trainer, and Coach at CancerMed (Sole Proprietorship)
My main activity was to help 21 pharmaceutical companies to develop material like brochures, slide decks, trainings, and webpages that help healthcare professionals to get the most out of their drug so patients can benefit from the lifesaving or life-prolonging cancer treatments for a longer period and with improved quality of life. I served the following pharmaceutical companies: Amgen, AstraZeneca, Baxalta, Bayer, Becton Dickinson, Boehringer Ingelheim, Bristol-Myers Squibb, EusaPharma, Galera, GlaxoSmithKline, Helsinn, Ipsen, Lilly, Lifestream Pharma, Merck Serono, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi Aventis, and Takeda. I also served as a trainer.
Explore my Track Record here.
2012/03 – present | Founder, Chief Executive Officer (CEO) & Senior Side Effects Researcher at IMPAQTT Foundation
Impaqtt is CancerMed’s Side Effects Research & Dissemination Foundation. I founded the Impaqtt Foundation in 2012. The mission of the foundation is to enlighten the treatment of patients with cancer and advance the lives of millions of people living with cancer worldwide by facilitating breakthrough research and sharing cutting-edge knowledge about side effects resulting from cancer medication. Only through a joint approach in which we bring together knowledge & funds we are able to improve the lives of people with cancer globally.
Learn more about the Impaqtt Foundation here.
2013/07 – 2015/07 | Researcher at the Department of Medical Oncology at Leiden University Medical Centre (LUMC), Leiden, The Netherlands
As part of my PhD program, I worked as a researcher to perform the study handlings for the patients included in the LUMC in my two clinical trials.
2007/11 - 2012/05 | Head of the Science Office at Esperanz
Esperanz was an overarching oncology organization for the three hospitals in Zaandam (Zaans Medical Center), Purmerend (Waterland Hospital, now Dijklander) and Hoorn (Westfriesgasthuis, now Dijklander). As Head of the Science Office, I was responsible for all processes (e.g. substantive, business, financial, and logistical processes) of all clinical trials carried out under the umbrella of Esperanz.
2001/06 – 2007/09 | Board member at Institutional Review Board (IRB) Noord Holland Alkmaar, The Netherlands. In Dutch ‘Medisch Ethische Toetsings Commissie’ (METC).
The METC oversees the conduct of clinical research for the region Noord Holland. I was a member since its founding in June 2001.
1997/09 – 2012/05 | Clinical Nurse Specialist, Research Coordinator & IRB member at Waterland Hospital (now Dijklander), Purmerend, The Netherlands.
1992/03 – 1997/08 | Registered Nurse at St. Lucas Andreas Hospital, Location Lucas (Now OLVG-West), Amsterdam, The Netherlands
First 1,5 years I worked at the lung disease/ thoracic surgery/ neurosurgery department, then at the internal medicine department (oncology/ hematology/ gastroenterology).
1990/07 – 1991/07 | Homecare Nurse at Foundation Home Care for Disabled, Eindhoven, The Netherlands. (Stichting Thuiszorg Voor Gehandicapten)
Two weeks in July 1990 and three weeks in July 1991. This was 24-hour home care during the holiday period.
1984/07 – 1985/07 | Nurse student at St. Josef Hospital, Moers, Germany
I worked as a nurse student on a surgical ward for women, combined with the Home Economics School (Haushaltsschule) because I was not 18 years at that time, so I was obligated to attend class once a week.
2008/04 – 2019/09 | External PhD candidate at the Department of Medical Oncology at Leiden University Medical Centre (LUMC), Leiden, The Netherlands. Result: PhD Degree.
The multinational interdisciplinary research program (Memorial Sloan-Kettering Cancer Center and City of Hope, USA; The University of Adelaide, Adelaide, Australia, and the Netherlands), was put together with patients, medical oncologists, dermatologists, dentists, a quality of life specialist (medical psychologist) a FACIT-member, a pathologist, a statistician, and nurses.
Supervisors: ME Lacouture (dermatologist, Memorial Sloan-Kettering Cancer Center, New York, USA), JB Epstein (oral surgeon oncology, City of Hope, Duarte, USA), JWR Nortier (medical oncologist, LUMC), AA Kaptein (psychologist, LUMC), and H Gelderblom (medical oncologist, LUMC).
The central question of my dissertation was whether available methods and instruments can serve as a basis for the realization of an integrated patient-driven approach to targeted therapy-associated adverse events for the best outcome possible. We performed the following studies:
1. Compose literature reviews
2. Developing DERETT, translating FACT-EGFRI-18, VHNSS2.0, and validating these assessment tools.
3. Clinical trial (NCT01136005): Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of papulopustular eruption in Patients Receiving EGFRI: BeCet.
4. Clinical trial (NCT01265810): Phase III Randomized Double-blind Crossover trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor patients receiving targeted therapy: COMTT.
On September 4, 2019, I defended my thesis entitled ‘Towards a patient-driven approach to adverse events of targeted agents in oncology’ successfully.
1993/08 – 1997/06 | Health Sciences; subdivision Nursing Science (Gezondheidswetenschappen, afstudeerrichting Verplegingswetenschap) at University of Utrecht (UU), Utrecht, The Netherlands. Result: MSc Degree
Supervisors: RH van Linge, JAM Winnubst; My graduation project was about decision-making & implementation strategies regarding primary process innovations. Title of the thesis: Perception of the Implementation Interventions: Research about the perception of the applied implementation interventions related to the nursing process for nurses in the workplace.
1992/10 – 1993/07 | Mathematics (VWO) at Leidse Onderwijsinstellingen (LOI), Leiderdorp, The Netherlands.
I needed to have Mathematics on Highschool level, to be able to study Health Sciences. I followed this course from home.
1991/08 – 1992/01 | Nursing Education at Hoger Beroeps Onderwijs Verpleegkunde (HBO-V), Inholland Alkmaar, The Netherlands. Result: BSc Degree.
Class 4 because I moved to Alkmaar.
Internship of 3½ months at Westfries Gasthuis, Hoorn, department of lung diseases.
1987/08 – 1991/07 | Nursing Education at Hoger Beroeps Onderwijs Verpleegkunde (HBO-V), Inholland Eindhoven, The Netherlands.
Internships of 3½ months at:
• Elkerliek, Helmond (General Hospital), first-class medical care department
• Grote Beek, Eindhoven (Psychiatry), supportive follow-up treatment
• Eckartdal, Eindhoven (Mentally Disabled), elderly people with strongly deviant behavior
1985/08 – 1987/07 | Senior General Secondary Education (Hoger Algemeen Voortgezet Onderwijs (HAVO)), at Jerusalem Venray, The Netherlands
Because I moved to the Netherlands but didn’t have a Dutch Education, I needed to do classes 4 & 5 to be able to receive the Dutch equivalent of the German Certification.
1984/08 – 1985/07 | Home Economics School (Haushaltsschule), Moers, Germany
The home economics school prepares for further training. Once a week, because I was not 18 years at that time, I was obligated to attend class once a week.
1978/08 – 1984/07 | Senior General Secondary Education at Realschule Rheinkamp, Moers, Germany.
1972/09 – 1978/07 | Elementary School (Grundschule) at Waldschule Schwafheim, Moers, Germany.
Coaching & Mentoring: 5
Financial Acquisition: 4
Review Experience: 5
2021/10 - 2022/04 | Compelling Copywriting at Wendy White.
How to attract staff & customers with your message
2021/01 - present | Master of Business Administration (MBA) at Sigrun GMBH. Zurich, Switzerland.
Online education with a specialization in entrepreneurship, content development, policy & strategy, and marketing & sales.
2021/01 - 2021/05 | Branding & Design School at Carola Beleeft, as part of To-Cie.
2014/01 - 2017/12 | Master of Business Administration (MBA) at Open Circles Academy, Amsterdam, The Netherlands.
(e.g. How to write a book in 28 days, and Master Presenter)
2015/10/14 – 2015/0/15 | WHHT Congres - Moet alles wat kan & kan alles wat moet. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2015/04/12 – 2015/04/14 | Statistical Aspects of Clinical Trials. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2015/02/19 | PhD-candidate Day 2015: ‘The only way is up!’ Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2014/02/16 – 2014/02/17 | (BROK) Wet- en Regelgeving voor senior onderzoekers. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2012/11/13 | Van CRF tot Database 2012-II. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2012/10/07 – 2012/10/08 | Dealing with Conflicting Demands. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2012/02/01 | PhD-candidate Day 2012. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2011/10/25 – 2011/10/27 | Meta Analyses. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2010/10/20 | PhD-candidate day 2010. Boerhaave Courseat Leiden University Medical Centre, Leiden, The Netherlands
2009/10 | Clinical Drug Research in Oncology. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
(Klinisch Geneesmiddelenonderzoek in de Oncologie).
2009/05/03 – 2009/05/07 | Clinical Trials. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2009/03 – 2009/04 | Communication in Science II. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands. A 7-day course. English oral and writing skills (abstract, article, poster, and PowerPoint presentation of own research).
2009/01/19 – 2009/02/16 | Communication in Science I. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
2008/11/25 – 2008/11/26 & 2010/4 | Design and interpretation of research in human subjects. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands Opzet en Interpretatie van Mensgebonden Onderzoek.
2008/09 | Good Clinical Practice (GCP). Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands.
2008/06/16 | Introduction day for new PhD students. Boerhaave Course at Leiden University Medical Centre, Leiden, The Netherlands
Introductiedag nieuwe promovendi.
2006/04 – 2006/06 | National Training Program Medical Ethical Review at Nationaal Opleidingstraject Medisch-Ethische Toetsing, NOMET.
2000 | Medical-Ethics Committees at Instituut voor Gezondheidsethiek (Medisch-ethische commissies)
1999 | Project Work at Van Aggelen & Partners BV. (Projectmatig werken)
1999/01 – 1999/02 | Work conference Good Clinical. Practice & Law Medical Research on Humans (Wet Medisch-Wetenschappelijk Onderzoek met Mensen)
1998/01 | Communication in Oncology at the Comprehensive Cancer Centre Amsterdam (Integraal Kankercentrum Amsterdam), Amsterdam, The Netherlands. (Communiceren in de oncologie)
1997/10 – 1998/01 | Basic Training Oncology at Waterland Hospital, Purmerend, The Netherlands.
1997 | Writing for Publication at Hogeschool Utrecht (College of Utrecht)
Publiceren voor afgestudeerde wetenschappers
1993 | Basic Training Oncology at St. Lucas Hospital, Amsterdam, The Netherlands.
1997 – 2004 | Society of Masters in Nursing (Vereniging voor Verplegingswetenschappers; VerVe)
Board member from 1998- 2001
1997/09 - 2017/09 | Nursing and Care Netherlands - Oncology (Verpleging en Verzorging Nederland; V&VN) - Oncologie
1998/03 – present | National Consultation Oncology Nurses (Landelijk Overleg Oncologie Verpleegkundigen; LOOV))
Board member from 1998 - present
2007/06 – 2014/02 | SIG (Special Interest Group) Immuno/Targeted Therapy
Chairman project group ‘Brochures and guidelines’ and active member of the project groups 'conference committee' and 'education'.
2007/03 – present | Oncology Nursing Society; ONS
1997/09 – present | European Oncology Nursing Society; EONS
2007/03 – present | Dutch Breast Cancer Trialists’ Group (Borstkanker Onderzoek Groep; BOOG) http://www.boogstudycenter.nl/organisatie/boog-organisation-in-english-85.html Chairman of the nursing advisory board BOOG-PIVOTAL from June 2008 –June 2013
2010/09 - present | Multinational Association of Supportive Care in Cancer; MASCC
Ambassador and active member of the Oncodermatology, Mucositis, and Education Study Groups of the MASCC/ISOO alliance which works on treatment recommendations for the management of skin reactions associated with anticancer therapies and empanel evidence-based clinical practice guidelines for mucositis. The Oncodermatology Study Group has undertaken the project of determining treatment recommendations for the management of skin reactions caused by EGFRI agents. As a member of the Study Group, I volunteered to review and evaluate evidence-based research and articles in the skin reactions category “dry skin”. The Mucositis Study Group has over 250 international researchers interested in mucositis. The Mucositis Study Group's major goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis associated with anticancer therapies. A major current effort of the Mucositis Study Group is the updating of evidence-based clinical practice guidelines for mucositis.
2012/09 - present | European School of Oncology; e-ESO
e-ESO is a free platform created by the European School of Oncology to provide e-learning opportunities for oncology professionals and other physicians interested in oncology.
2013/02 – present | American Society of Clinical Oncology; ASCO
2013/06 – present | International Society of Oral Oncology; ISOO
See also: Board of directors
2018/01 -present | Advanced Breast Cancer; ABC
Faculty Member of ABC4 and 5.
2018/01 - present | Advanced Breast Cancer; ABC Global Alliance
The ABC Global Alliance established in 2016 as an initiative of the European School of Oncology and now registered as a non-profit association in Portugal, is a multi-stakeholder platform for all those interested in collaborating on common projects relating to advanced breast cancer (ABC) around the world.
Research Grants: AstraZeneca 5K, OthoBiotech 7.5K, EusaPharma 10K, Novartis 13.5K, Amgen 15K, Roche 15K, Pfizer 16K, Bayer 20K, GlaxoSmithKline 20K.
Travel Grants: EusaPharma, Amgen, Novartis, OncoWijs, MerckSerono, V&VN Oncology, Comprehensive Cancer Center (IKA), MASCC.
Training Grants: Comprehensive Cancer Center (IKA): 2011; Dermatological assessment training; Memorial Sloan-Kettering Cancer Center, Dermatology Service, USA
Novartis: 2012; Oral Cavity assessment training; University of Connecticut Health Center, Department of Oral Health and Diagnostic Sciences, USA.
Workshop Grant: Unrestricted Grant for a non-CME workshop at the annual society meeting of MASCC in Berlin, 2013. Merck and Bayer participated in a total of 12K.
Symposium Grants: Unrestricted Grants for the first Impaqtt Symposium on September 4, 2019, from Lifestream Pharma, Caresse Cosmetics, Bayer, Pfizer, Ipsen, Amgen, EusaPharma, Lilly, Merck, Nordic Pharma, and Novartis participated in a total of 19K.
Crowdfunding: To be able to develop the TARGET-app to help patients assess, grade, and treat common side effects by themselves, I organized a booster campaign in 2020/2021. We reached our goal, 25K, on September 4, 2021. Continue reading at https://thetargetsystem.com
2008-06 – 2013-06 | BOOG-PIVOTAL (Borstkanker Onderzoek Groep; BOOG). Member of the Dutch Breast Cancer Trialists’ Group since March 2007. The BOOG is a collaborative study group that was founded in April 2001 with the aim of initiating, promoting, coordinating, and facilitating clinical breast cancer trials. In particular, the group's focus lies on the development and conduct of phase II and III trials. In June 2008 I became the founder and chair of the Nursing Advisory Board BOOG-PIVOTAL. The Nursing Advisory Board provides practical and logistical advice about the implementation of BOOG trials in clinical settings. The group also participates in the development of nursing protocols and in the review of study information for patients. I was chair of the Nursing Advisory Board BOOG-PIVOTAL till June 2013 and am still a BOOG member.
2007-06 – 2014-02 | Special Interest Group (SIG) Targeted- & Immunotherapy (Doelgerichte en immunotherapie) of the Dutch Oncology Nursing Society (V&VN Oncologie). The Project Group ‘Brochures and guidelines’ writes targeted agent-specific brochures for patients and health care providers. A national guideline about the management of side effects of targeted therapies was developed. I was also an active member of the project groups 'conference committee' and 'education' of the SIG Immuno/targeted therapy. The Conference committee organizes SIG sessions addressing Immunotherapy and Targeted Therapy during the annual National Oncology Nursing Conference. The Education group developed the Dutch version of the TARGET course, originally developed by EONS, the European Oncology Nursing Society. I also served as a speaker. The Education group develops also an e-learning program, wherein I was responsible for the Oncodermatology section.
2013/06 – 2015/06 | International Society of Oral Oncology (ISOO)
A MASCC/ISOO alliance that promotes scientific exchange among health care professionals in oncology, cytotoxic therapy, and its impact on the oral environment.
2008/06 – 2013/06 | Nursing Advisory Board BOOG-PIVOTAL
Founder and chair. BOOG is the Dutch Breast Cancer Trialists’ Group (Borstkanker Onderzoek Groep). The Nursing Advisory Board provides practical and logistical advice about the implementation of BOOG trials in clinical settings. The group also participates in the development of nursing protocols and in the review of study information for patients. I was chair of the Nursing Advisory Board BOOG-PIVOTAL till June 2013 and I’m still a BOOG member.
2001/06 – 2007/09 | Institutional Review Board (IRB) Noord Holland
Medical Ethics Review Committee (METC) Noord Holland Alkmaar, The Netherlands.
The METC oversees the conduct of clinical research for the region of Noord Holland.
1998/03 – 2006/03 | Institutional Review Board (IRB) Waterland Hospital
Medical Ethics Committee (MEC) Waterland Hospital, Purmerend, The Netherlands.
The MEC oversees the conduct of clinical research and ethical issues for the Waterland Hospital.
1998/03 – present | National Consultation Oncology Nurses (Landelijk Overleg Oncologie Verpleegkundigen; LOOV)
Members are nurses who are active in the development of new nursing skills and knowledge. The goal of this group is to exchange information related to institutional and national best practices in oncology nursing so as to lower the threshold for the implementation and dissemination of innovative advances in the field. Between 2018 and 2021 I had a break in the board membership due to my PhD project.
1997 – 2004 | Society of Masters in Nursing (Vereniging voor Verplegingswetenschappers; VerVe)
The objective of VerVe was to develop and maintain a network of nurses with advanced scientific training and experience. VerVe researched and applied results in promoting and supporting professional practice which was performed by organizing lectures and the bi-annually Flemish-Dutch Scientific Congress. In addition, I was the contact person for the Netherlands Institute for Hospital Accreditation (NIAZ).
Peer reviewer for Eur J Oncol Nurs, Supp Care Cancer, Recent Pat Antiinfect Drug Discov, Cancer Invest, Cancer, Medicinal Research Reviews, Lancet, Breast, Journal of Pain and Symptom, Cancer Medicine, Expert Opinion On Drug Safety, Oral Oncology, MASCC study groups, etc.
Abstract reviewer for MASCC and ABC.
Thesis reviewer for Master in Advanced Nursing Practice (MANP) and bachelor students.
2021/12 - present | Patient Advocate BVN - Borstkankervereniging Nederland
2020/12 - present | Fadia Survive and Thrive's Scientific Advisory Board
Learn here about the Fadia Survive and Thrive Foundation.
2020/09 - present | WelzijnWonenPlus
WelzijnWonenPlus is there to help people so that vulnerable people living at home receive appropriate help if they need it, with the focus on “participation” and “everyone matters”. This support does not come from us but from the direct living environment of people who look after each other and want to be there for each other. We want to make that possible. We believe in a society in which people are there for each other and help each other when necessary. With WelzijnWonenPlus we are committed to achieving this. I help with grocery shopping, I am a driver to COVID vaccination locations, and other kinds of help.